OTCMKTS:SVNTQ - Savient Pharmaceuticals Stock Price, News, & Analysis

Sign in or create an account to add this stock to your watchlist.
Previous Close$0.0019
Today's RangeN/A
52-Week RangeN/A
VolumeN/A
Average Volume340,036 shs
Market CapitalizationN/A
P/E RatioN/A
Dividend YieldN/A
BetaN/A
Savient Pharmaceuticals, Inc. (Savient), incorporated in 1980, is a specialty biopharmaceutical company focused on commercializing KRYSTEXXA (pegloticase) in the United States and completing the development and seeking regulatory approval outside of the United States for KRYSTEXXA, particularly in the European Union. The Company also sells and distributes branded and generic versions of oxandrolone, a drug used to promote weight gain following involuntary weight loss. In October 2013, the Company announced that it has elected to file voluntary petitions under Chapter 11 of the Bankruptcy Code in the United States Bankruptcy Court for the District of Delaware (the Court). Effective January 10, 2014, Crealta Pharmaceuticals LLC, a majority owned unit of GTCR LLC acquired Savient Pharmaceuticals Inc.

Receive SVNTQ News and Ratings via Email

Sign-up to receive the latest news and ratings for SVNTQ and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry N/A
Sub-IndustryN/A
SectorN/A
Current SymbolOTCMKTS:SVNTQ
Previous SymbolNASDAQ:SVNT
CUSIPN/A
Phone+1-732-4189300

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A

Profitability

Miscellaneous

EmployeesN/A
Next Earnings DateN/A
OptionableNot Optionable

Savient Pharmaceuticals (OTCMKTS:SVNTQ) Frequently Asked Questions

What is Savient Pharmaceuticals' stock symbol?

Savient Pharmaceuticals trades on the OTCMKTS under the ticker symbol "SVNTQ."

Has Savient Pharmaceuticals been receiving favorable news coverage?

News headlines about SVNTQ stock have trended somewhat negative on Sunday, InfoTrie reports. InfoTrie scores the sentiment of press coverage by reviewing more than six thousand news and blog sources in real-time. The firm ranks coverage of companies on a scale of negative five to five, with scores closest to five being the most favorable. Savient Pharmaceuticals earned a news impact score of -1.4 on InfoTrie's scale. They also assigned news headlines about the biopharmaceutical company a news buzz of 0.0 out of 10, meaning that recent press coverage is extremely unlikely to have an impact on the stock's share price in the next few days.

What other stocks do shareholders of Savient Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Savient Pharmaceuticals investors own include QUALCOMM (QCOM), Bristol-Myers Squibb (BMY), Altria Group (MO), Mcdonald's (MCD), Silicon Motion Technology (SIMO), Tempur Sealy International (TPX), Weibo (WB), Methanex (MEOH), Kraft Heinz (KHC) and Texas Instruments (TXN).

How do I buy shares of Savient Pharmaceuticals?

Shares of SVNTQ can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Savient Pharmaceuticals' official website?

The official website for Savient Pharmaceuticals is http://www.savientpharma.com/.

How can I contact Savient Pharmaceuticals?

Savient Pharmaceuticals' mailing address is 1 Tower Center Blvd, EAST BRUNSWICK, NJ 08816-1145, United States. The biopharmaceutical company can be reached via phone at +1-732-4189300.


MarketBeat Community Rating for Savient Pharmaceuticals (OTCMKTS SVNTQ)

Community Ranking:  2.1 out of 5 (star star)
Outperform Votes:  69 (Vote Outperform)
Underperform Votes:  98 (Vote Underperform)
Total Votes:  167
MarketBeat's community ratings are surveys of what our community members think about Savient Pharmaceuticals and other stocks. Vote "Outperform" if you believe SVNTQ will outperform the S&P 500 over the long term. Vote "Underperform" if you believe SVNTQ will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 3/24/2019 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel